← Back to Search

Small Molecule

FX-322 High Dose for Sensorineural Hearing Loss

Phase 1 & 2
Waitlist Available
Led By George Atiee, MD
Research Sponsored by Frequency Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up data points taken pre-dose and 0.5, 1, 2, 4, 8, 24 hours post-dose

Summary

This is a phase 1/2 study of FX-322 at two dose levels compared to placebo in male and female adults otherwise healthy with stable sensorineural hearing loss.

Eligible Conditions
  • Sensorineural Hearing Loss

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~data points taken pre-dose and 0.5, 1, 2, 4, 8, 24 hours post-dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and data points taken pre-dose and 0.5, 1, 2, 4, 8, 24 hours post-dose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Treatment-emergent Adverse Event(s) (TEAEs)
Secondary study objectives
AUClast
CL/F
Cmax
+2 more

Side effects data

From 2018 Phase 1 & 2 trial • 23 Patients • NCT03616223
71%
Ear Discomfort
14%
Viral Upper Respiratory Tract Infection
14%
Ear Pain
14%
Oropharyngeal Pain
14%
Ear Pruritus
14%
Toothache
14%
Dizziness
14%
Muscle Spasms
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo-Low Dose
Placebo-High Dose
Pooled Placebo
FX-322 Low Dose
FX-322 High Dose

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: FX-322 Low DoseExperimental Treatment1 Intervention
Cohort of 8. Single intratympanic injection
Group II: FX-322 High DoseExperimental Treatment1 Intervention
Cohort of 8. Single intratympanic injection
Group III: Placebo-Low DosePlacebo Group1 Intervention
Cohort of 4. Single intratympanic injection
Group IV: Placebo-High DosePlacebo Group1 Intervention
Cohort of 4. Single intratympanic injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FX-322
2020
Completed Phase 2
~240

Find a Location

Who is running the clinical trial?

Frequency TherapeuticsLead Sponsor
6 Previous Clinical Trials
313 Total Patients Enrolled
George Atiee, MDPrincipal InvestigatorWorldwide Clinical Trials
5 Previous Clinical Trials
449 Total Patients Enrolled
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top